Commentary Window for change

Now that President Clinton's health care plan is dead, the biotechnology industry has an opportunity to turn to other items of concern in the regulatory and legislative arena. But the window of opportunity is brief - no more than the 12 months to January 1996 that incoming Speaker Newt Gingrich has identified as the time of potential compromise before the 1996 presidential campaign ends all hope.

The Biotechnology Industry Organization already has tackled the trend at the Patent and Trademark Office toward granting biotech patents only on molecules with human clinical data -and come up with a promise of a quick and favorable change from Patent Commissioner Bruce Lehman.